Pieris Pharmaceuticals, Inc.
NASDAQ:PIRS
16.9825 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 42.81 | 25.902 | 31.418 | 29.323 | 46.279 | 29.101 | 25.275 | 5.831 | 2.932 | 5.365 | 9.88 | 11.383 |
| Cost of Revenue
| 41.801 | 2.78 | 2.368 | 46.531 | 54.996 | 0 | 0 | 0 | 0 | 0 | -2.547 | 0 |
| Gross Profit
| 1.009 | 23.122 | 29.05 | -17.208 | -8.717 | 29.101 | 25.275 | 5.831 | 2.932 | 5.365 | 12.427 | 11.383 |
| Gross Profit Ratio
| 0.024 | 0.893 | 0.925 | -0.587 | -0.188 | 1 | 1 | 1 | 1 | 1 | 1.258 | 1 |
| Reseach & Development Expenses
| 41.801 | 52.982 | 66.656 | 46.531 | 54.996 | 41.49 | 22.285 | 19.699 | 8.245 | 5.6 | 9.412 | 10.855 |
| General & Administrative Expenses
| 16.853 | 16.394 | 16.593 | 16.713 | 18.44 | 18.442 | 17.584 | 8.891 | 8.368 | 6.963 | 2.462 | 2.709 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.281 |
| SG&A
| 16.853 | 16.394 | 16.593 | 16.713 | 18.44 | 18.442 | 17.584 | 8.891 | 8.368 | 6.963 | 2.462 | 2.989 |
| Other Expenses
| -27.889 | -8.173 | -3.685 | -3.656 | -0.026 | 1.803 | -2.102 | 0.12 | 0.011 | 0.003 | 0.006 | 0 |
| Operating Expenses
| 30.765 | 61.203 | 79.564 | 63.244 | 73.436 | 59.932 | 39.869 | 28.59 | 16.613 | 12.563 | 9.326 | 13.527 |
| Operating Income
| -29.756 | -43.474 | -51.831 | -33.921 | -27.157 | -30.831 | -14.594 | -22.759 | -13.681 | -7.198 | 0.554 | -2.18 |
| Operating Income Ratio
| -0.695 | -1.678 | -1.65 | -1.157 | -0.587 | -1.059 | -0.577 | -3.903 | -4.666 | -1.342 | 0.056 | -0.192 |
| Total Other Income Expenses Net
| 5.213 | 10.197 | 6.093 | -3.145 | 1.688 | 3.765 | -2.102 | 0.12 | 0.011 | 0.003 | 0.006 | -0.141 |
| Income Before Tax
| -24.543 | -33.277 | -45.738 | -37.066 | -25.469 | -27.066 | -16.544 | -22.637 | -13.855 | -9.85 | 0.066 | -2.321 |
| Income Before Tax Ratio
| -0.573 | -1.285 | -1.456 | -1.264 | -0.55 | -0.93 | -0.655 | -3.882 | -4.725 | -1.836 | 0.007 | -0.204 |
| Income Tax Expense
| 13.912 | -2.024 | -2.372 | 0.164 | -1.714 | -0.312 | 1.103 | 0.162 | 0.204 | -0 | 0.488 | 0 |
| Net Income
| -24.543 | -31.253 | -43.366 | -37.23 | -23.755 | -26.754 | -17.647 | -22.799 | -14.059 | -9.85 | 0.066 | -2.321 |
| Net Income Ratio
| -0.573 | -1.207 | -1.38 | -1.27 | -0.513 | -0.919 | -0.698 | -3.91 | -4.795 | -1.836 | 0.007 | -0.204 |
| EPS
| -21.8 | -33.71 | -53.75 | -54.67 | -37.54 | -40.32 | -32.14 | -43.73 | -32.7 | -20.62 | 0.45 | -38.68 |
| EPS Diluted
| -21.8 | -33.71 | -53.75 | -54.67 | -37.54 | -40.32 | -32.14 | -43.73 | -32.7 | -20.62 | 0.45 | -38.68 |
| EBITDA
| -13.94 | -35.301 | -48.146 | -31.794 | -26.117 | -30.261 | -14.225 | -22.759 | -13.67 | -7.195 | 0.945 | -1.802 |
| EBITDA Ratio
| -0.326 | -1.363 | -1.532 | -1.084 | -0.564 | -1.04 | -0.563 | -3.903 | -4.663 | -1.341 | 0.096 | -0.158 |